The imbalance between osteoblasts and osteoclasts can lead to pathological conditions such as osteoporosis. It has been reported that opioid adversely affect the skeletal system, but it is inconsistent. Remifentanil is currently used as an adjuvant analgesic drug in general anesthesia and sedation. The aim of the present study was to investigate the effect of remifentanil on the osteoblast differentiation and mechanism involved in this effect. Methods: The C2C12 cells (mouse pluripotent mesenchymal cell line) were used as preosteoblast. Osteoblastic differentiation potency was determined by alkaline phosphatase (ALP) staining. C2C12 cell migration by remifentanil was evaluated using Boyden chamber migration assay. The expression of Runx2 and osterix was evaluated by RT-PCT and western blot analysis to investigate the mechanism involved in remifentanil-mediated osteoblast differentiation. Results: ALP staining showed that remifentanil increased significantly osteoblast differentiation. In Boyden chamber migration assay, C2C12 cell migration was increased by remifentanil. RT-PCR and western blot analysis showed that the expression of Runx2 and osterix was upregulated by remifentanil. Conclusions: We demonstrated that remifentanil increased osteoblast differentiation in vitro by upregulation of Runx2 and osterix expression. Therefore, remifentanil has the potential for assisting with bone formation and bone healing.
INTRODUCTION
Bone is a specialized form of connective tissue that is constantly being remodeled. It is formed via three sequential processes: bone extracellular matrix is synthesized by osteoblasts (osteogenesis); bone is resorpted by osteoclast to form its shape in response to the physical environment (modeling); and the milieu is changed to adjust to the demands of the growth (remodeling) [1] . Each of these processes is mediated by the balance of bone-forming osteoblasts and boneresorbing osteoclasts [2] . A shift in this balance toward the activation of osteoclasts results in many clinical diseases, such as osteopenia and osteoporosis. Osteoporosis has been emerging as a global health concern that affects a wide range of populations, especially in old age [3] . Recently, osteoblast activity is considered a potential therapeutic target to control the osteopenic disease.
Osteoblasts are bone-forming cells that synthesize bone matrix, regulate mineralization, and eventually differentiate into osteocytes, or bone lining cells. They originate from mesenchymal stem cells and can differentiate into mature osteoblasts [4] . Mesenchymal stem cells give rise to preosteoblasts via activation of master transcriptional regulator, runt-related transcription factor 2 (Runx2) [5] . Thereafter, the growth and differentiation of osteoblast proceed in three stages with specific gene expression; the cells proliferate continuously and express collagen type I (COL1A1), TGF-β, fibronectin, and osteoponin (OPN); the extracellular matrix matures and expresses several extracellular matrix proteins including alkaline phosphatase (ALP) and COL1A1; and the matrix mineralizes and becomes enriched with osteocalcin, bone sialoprotein (BSP), and OPN. Subsequently, the mature osteoblasts with cuboidal shape is developed [6, 7] .
Remifentanil is a synthetic opioid acting on μ-opioid receptors, which is rapidly metabolized by nonspecific esterases in the plasma, giving it the characteristic of having very short onset and offset times [8] . Due to these properties, remifentanil has been used widely as an adjuvant analgesic drug during general anesthesia and sedation. The effect of remifentanil on osteoblasts has been investigated in previous studies. Yoon et al. [9] reported that remifentanil has a protective effect against oxidative stress on human osteoblasts. In another study, it was reported that pre-conditioning with remifentanil enhanced osteoblast maturation under hypoxia-reoxygenation conditions [10] . In the current study, we investigated the effect of remifentanil on osteoblast differentiation under normoxia state using C2C12 cells.
We also investigated the mechanism of remifentanilmediated osteoblast differentiation by analyzing osteoblastogenic genes expression.
MATERIALS AND METHODS

Reagents
Remifentanil was obtained from GlaxoSmithKline Pharmaceuticals (Rockville, MD, USA). The C2C12 cells (mouse pluripotent mesenchymal cell line) were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Leukocyte Alkaline Phosphatase Kit (for ALP staining) was purchased from Sigma-Aldrich (St. Louis, MO). Anti-Runx2 antibodies were purchased from MBL (Nagoya, Japan), anti-osterix antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All other chemicals and reagents were purchased from Sigma-Aldrich.
Cell culture and osteogenic differentiation
The C2C12 cells were maintained in Dulbecco's modified Eagle medium (DMEM; Gibco-BRL, Gaithersburg, MD, USA), containing 10% fetal bovine serum (FBS) and 1% antibiotics (50 U/ml of penicillin-G and 0.05 mg/ml of streptomycin) (Gibco-BRL), at 37°C in a humidified 5% CO 2 atmosphere. For the experiments, C2C12 cells were exposed to indicated dose of remifentanil. We assigned the group received no chemical treatment as a control group. For osteogenic differentiation of C2C12 cells, a mineralizing medium was used, which comprised of DMEM and 100 µg/ml bone morphogenic protein (BMP)-2. C2C12 cells processed with osteogenic differentiation were used as preosteoblasts. Media were changed every 48 h.
Cytotoxicity and cell proliferation assays
The effects of remifentanil on cell viability and proliferation were measured using the well-established 
Boyden chamber migration assay
To examine the cell migration capacity by chemo- 
Western blot analysis
Western blotting was conducted following a standard procedure. Briefly, C2C12 cells were disrupted in a RIPA lysis buffer (50 mM Tris; pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 1.5 mM MgCl 2 , 1 mM EGTA, 1%
Triton X-100, 10 mM NaF, and complete protease inhibitor cocktail). The protein concentrations of cell lysates were determined using a detergent-compatible protein assay kit (Bio-Rad Laboratories, CA, USA), and 30-45 µg of total protein was resolved using 8-10%
SDS-polyacrylamide gel electrophoresis. Separated proteins 
Statistical analysis
Data are presented as the mean ± standard deviation (SD) of results from three independent experiments. The Student's t-test was used to determine the significance of differences between two groups. Differences with a p value < 0.05 were regarded as being statistically significant and denoted using an asterisk.
RESULTS
Remifentanil did not exert cytotoxic effects or alter cell proliferation in C2C12 cells
The effect of remifentanil on the cell viability of C2C12 cells was examined using the MTT assay. As shown in Fig. 1A , the MTT assay results indicated that the viability of C2C12 cells was not affected by various concentrations of remifentanil (0-100 ng/ml). The proliferation of C2C12 cells increased with time, but there were no significant differences observed with increasing doses of remifentanil (Fig. 1B) .
Remifentanil increased osteoblast differentiation of preosteoblastic C2C12 cells
To examine the role of remifentanil in osteoblast differentiation, C2C12 cells were cultured in osteogenic media containing BMP-2 and treated with remifentanil (0, 1, and 10 ng/ml). After 24 and 72 h, the cultured C2C12 cells were stained for ALP. As shown in Fig. 2A and B, 10 ng/ml of remifentanil significantly increased ALP staining and the ALP-positive area of C2C12 cells compared to BMP-2 group (Fig. 2A, B ). This result shows that remifentanil promoted osteoblast differentiation in the preosteoblastic C2C12 cells.
Remifentanil increased cell migration of C2C12 cells in the Boyden chamber migration assay
The migration of C2C12 cells was evaluated using the Boyden chamber migration assay. As shown in Fig. 3A , remifentanil increased migration of C2C12 cells compared to control. In addition, migrated cell numbers were significantly increased after transfection with 10 and 50 ng/ml of remifentanil compared to the control (Fig. 3B ).
Remifentanil upregulated the expression of Runx2 and osterix
We demonstrated that remifentanil increased osteoblast differentiation (Fig. 2) . To establish the mechanism involved in the effect of remifentanil on osteoblast The protein expression of Runx2 and osterix were evaluated in C2C12 cells using western blot analysis after remifentanil treatment for 4 days. The protein level of Runx2 significantly increased after treatment with both 10 and 50 ng/ml of remifentanil, compared to the BMP-2 group (Fig. 4B, C) . Remifentanil treatment increased the protein expression of Runx2 in a dose dependent manner.
As shown in Fig. 4D , the protein expression of osterix significantly increased after 50 ng/ml of remifentanil During bone remodeling, preosteoblasts or their precursors migrate into bone resorption cavities and start to form bone by filling in the bone cavities [17] . Therefore, preosteoblastic cell migration is a critical process in bone remodeling to preserve bone mass [18] . In addition, it is crucial for the repair of bone damage caused by pathologic states, such as osteoporosis and bone fracture.
Preosteoblasts and osteoblasts have been reported to migrate toward chemo-attractant, but the key molecules involved in osteoblastic cell migration have not yet been studied [19] . In the present study, we have demonstrated that remifentanil increases cell migration of preosteoblasts, suggesting that remifentanil can contribute to bone healing by inducing preosteoblastic cell migration.
This study has shown that remifentanil increases osteoblastic differentiation by upregulating the expression of two key osteogenic transcription factors, Runx2 and osterix. Runx2 is an essential transcription factor that gives rise to the osteoblast lineage from mesenchymal stem cells, and once Runx2 is activated, the cells are defined as pre-osteoblasts in the osteoblast lineage [7] .
Osterix is a zinc-finger transcription factor and has been shown to be required for bone formation and mineralization in vivo. In addition, osterix is a known downstream target of Runx2 during osteoblast differentiation [20] . Y. Nishio et al. [21] reported in their study that Runx2 binds to the osterix promoter and leads to the activation of osterix transcriptional regulation. Runx2
and osterix have been reported to interact and cooperatively regulate the expression of bone-specific genes. Therefore, the upregulation of Runx2 is usually accompanied by the activation of osterix.
In conclusion, remifentanil increased osteoblast differentiation in vitro through the upregulation of Runx2 and osterix expression. In addition, preosteoblastic cell migration was enhanced by remifentanil treatment.
Although this study has some limitations with respect to being an in vitro study, and further studies are needed to fully elucidate our findings, it does suggest that remifentanil has the potential for assisting with bone formation and bone healing.
